I-Technivie - I-Hepatitis C Ulwazi Lwezidakamizwa

I-Technivie (i-ombitasvir + paritaprevir + ritonavir) iyinhlanganisela ye-dose inhlanganisela esetshenziswa ekwelapheni ukutheleleka okungapheli kwe- hepatitis C (HCV) . Lawa ma-agent amathathu ahlanganisa i-Technivie nawo ahlanganiswe emithini emibili ye-pilules ye-HCV, i- Viekira Pak .

I-Technivie yamukelwa ngoJulayi 24, 2015 yi-US Food and Drug Administration (FDA) yokusetshenziswa kubantu abadala kweminyaka engu-18 noma ngaphezulu ne-HCV genotype 4 ukutheleleka (GT4) ngaphandle kwe- cirrhosis .

I-Technivie yiyona yokwelashwa kwe-HCV yokuqala, ephelele-ngomlomo, e-interferon yama-HCV ye-GT4 engavamile ye-HCV, iningi labantu elibhekwa njengelikhuni ukuliphatha.

I-Technivie ibike ukuthi inezinga lokuphulukiswa kweziguli ezingu-100% ezingaphathwa kabi (iziguli "ze-naïve") esivivinyweni seSigaba IIb esenziwa kusukela ngo-Agasti 12, 2012 kuya kuNovemba 19, 2013.

Isilinganiso

Amaphilisi amabili (12.5mg ombitasvir, 75mg paritaprevir, 50mg ritonavir) ethathwa nsuku zonke ngesidlo ngaphandle kwesidingo sokudla okunamafutha aphezulu noma ama-caloric. Amaphilisi we-Technivie anama-pink, ama-oblong nama-film aphethwe, nge-"AV1" embossed ohlangothini olulodwa.

Ukubeka izincomo

I-Technivie inqunywe ngaphezu kwe-12-week course kanye ne-ribavirin (isidakamizwa esasetshenziswa ukuvimbela i-RNA synthesis). Umthamo ophakanyisiwe we-ribavirin usekelwe kwisisindo, kanje:

Inkambo ye-Technivie yezinyanga ezingu-12 ingacatshangelwa ukwelashwa kwe-naïve engakwazi ukubekezelela i-ribavirin.

Imiphumela Ejwayelekile Ejwayelekile

Imiphumela emibi kakhulu ehlobene nokusetshenziswa kwe-Technivie (okwenzeka okungenani iziguli ezingu-7%) yilezi:

Imithi yokwelapha

Izidakamizwa ezilandelayo akufanele zithathwe uma usebenzisa i-Technivie:

Ukungafani nokucabangela

I-Technivie ayinconywa iziguli ezinokukhubazeka okulinganayo kwe-hepatic (i-Child-Pugh score B) futhi iphikisana neziguli ezinokukhubazeka okukhulu (i-Child-Pugh score C).

I-Technivie iphikisana nokusetshenziswa kweziguli ezine-hypersensitivity eyaziwayo ku- ritonavir (okungukuthi, ngubani oye wabona uStevens-Johnson Syndrome noma i-necrolysis eyingozi ye-epidermal).

Ngenkathi i-Technivie eyedwa ingavunyelwe ukusetshenziselwa ukukhulelwa, inhlanganisela ye-Technivie ne-ribavirin ingeyona futhi kufanele ingasetshenziselwa abesifazane abakhulelwe noma amadoda abalingani babo abesifazane abakhulelwe. Ngokuphathelene nokuncelisa, kwakungekho izimo zezinhlamvu ezingavamile zokuthuthukiswa komntwana ezifundweni zesilwane; Ukubonisana okwebuchwepheshe kunconywa ukuxoxa ngezinzuzo ezikhona kanye nemiphumela emibi yokuncelisa ngenkathi ku-Technivie.

Umthombo:

I-US Food and Drug Administration (FDA). "I-FDA ivumela i-Technivie yokwelashwa kwesifo esingenasifo sofuba esingapheli 4." I-Silver Spring, e-Maryland; ukushicilelwa okukhishwe ngoJulayi 24, 2015.

Hézode, C .; Asselah, T .; Reddy, R .; et al. "I-Ombitasvir plus paritaprevir plus ritonavir noma ngaphandle kwe-ribavirin ezigulini ezitholakalayo zokwelapha nezifo zokwelapha ezine-genotype 4 ezingenayo igciwane lesandulela ngculaza (PEARL-I): isilingo esivulekile, esivulekile. I-Lancet. Juni 20, 2015; 384 (9986): 2502-2509.